{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:19:51Z","timestamp":1791332391857,"version":"4.3.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Elevated serum levels of the soluble form of IL-2 receptor \u03b1 (sIL-2R\u03b1) have been correlated with a poor prognosis in a variety of different types of cancers. However, its biologic relevance remains unclear and controversial. In patients with follicular B-cell non-Hodgkin lymphoma (FL), we observed that serum sIL-2R\u03b1 levels were elevated compared with controls and that elevated sIL-2R\u03b1 levels before treatment were associated with a poor outcome. To explore the mechanism by which sIL-2R\u03b1 may contribute to a poor prognosis in FL, we determined the effects of sIL-2R\u03b1 on IL-2 signaling and found that the sIL-2R\u03b1\u2013IL-2 complex promoted T-cell differentiation toward to inhibitory Treg cells rather than TH1 or TH17 cells. Shed by activated T cells that express membrane-bound IL-2R\u03b1, sIL-2R\u03b1 further enhanced IL-2\u2013mediated phosphorylation of Stat5 thereby significantly up-regulating Foxp3 expression in CD4+ T cells. We found that CD4+ T cells treated with either IL-2 or sIL-2R\u03b1\u2013IL-2 complex, but not with sIL-2R\u03b1 alone, inhibited the function of CD8+ T cells. Taken together, these results indicate that sIL-2R\u03b1 actually plays an active biologic role in FL by binding IL-2 and promoting IL-2 signaling rather than depleting IL-2 and blocking its function.<\/jats:p>","DOI":"10.1182\/blood-2011-03-340885","type":"journal-article","created":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T04:57:01Z","timestamp":1309496221000},"page":"2809-2820","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":128,"title":["Soluble IL-2R\u03b1 facilitates IL-2\u2013mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"118","author":[{"given":"Zhi-Zhang","family":"Yang","sequence":"first","affiliation":[{"name":"Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna M.","family":"Grote","sequence":"additional","affiliation":[{"name":"Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Ziesmer","sequence":"additional","affiliation":[{"name":"Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle K.","family":"Manske","sequence":"additional","affiliation":[{"name":"Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne J.","family":"Novak","sequence":"additional","affiliation":[{"name":"Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2019111806535764300_B1","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111806535764300_B2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","article-title":"Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.","volume":"25","author":"Glas","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111806535764300_B3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00277-009-0777-8","article-title":"Serum cytokines in follicular lymphoma. Correlation of TGF-beta and VEGF with survival.","volume":"89","author":"Labidi","year":"2010","journal-title":"Ann Hematol"},{"issue":"6","key":"2019111806535764300_B4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/10428190290026385","article-title":"Th1\/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin\u2019s lymphoma (NHL).","volume":"43","author":"Jones","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2019111806535764300_B5","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111806535764300_B6","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","article-title":"Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.","volume":"107","author":"Yang","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111806535764300_B7","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.4049\/jimmunol.178.7.4051","article-title":"Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3\/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells.","volume":"178","author":"Hilchey","year":"2007","journal-title":"J Immunol"},{"issue":"20","key":"2019111806535764300_B8","doi-asserted-by":"crossref","first-page":"10145","DOI":"10.1158\/0008-5472.CAN-06-1822","article-title":"Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin\u2019s lymphoma.","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res"},{"issue":"13","key":"2019111806535764300_B9","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-09-0266","article-title":"Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin\u2019s lymphoma.","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"2019111806535764300_B10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1074-7613(02)00367-9","article-title":"CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2.","volume":"17","author":"Malek","year":"2002","journal-title":"Immunity"},{"issue":"5","key":"2019111806535764300_B11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1084\/jem.20041179","article-title":"Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period.","volume":"201","author":"Bayer","year":"2005","journal-title":"J Exp Med"},{"issue":"11","key":"2019111806535764300_B12","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni1263","article-title":"A function for interleukin 2 in Foxp3-expressing regulatory T cells.","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat Immunol"},{"issue":"6","key":"2019111806535764300_B13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20020190","article-title":"Interleukin 2 signaling is required for CD4(+) regulatory T-cell function.","volume":"196","author":"Furtado","year":"2002","journal-title":"J Exp Med"},{"issue":"9","key":"2019111806535764300_B14","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.4049\/jimmunol.169.9.4850","article-title":"Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T-cell numbers.","volume":"169","author":"Almeida","year":"2002","journal-title":"J Immunol"},{"issue":"12","key":"2019111806535764300_B15","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.4049\/jimmunol.173.12.7259","article-title":"CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion.","volume":"173","author":"Curotto de Lafaille","year":"2004","journal-title":"J Immunol"},{"issue":"5","key":"2019111806535764300_B16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1084\/jem.20041982","article-title":"Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.","volume":"201","author":"Setoguchi","year":"2005","journal-title":"J Exp Med"},{"issue":"9","key":"2019111806535764300_B17","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1002\/eji.200425274","article-title":"Interleukin-2 is essential for CD4+CD25+ regulatory T-cell function.","volume":"34","author":"de la Rosa","year":"2004","journal-title":"Eur J Immunol"},{"issue":"11","key":"2019111806535764300_B18","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.4049\/jimmunol.172.11.6519","article-title":"Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T-cell suppressor function.","volume":"172","author":"Thornton","year":"2004","journal-title":"J Immunol"},{"issue":"5","key":"2019111806535764300_B19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/1043-4666(90)90062-X","article-title":"The molecular basis for the generation of the human soluble interleukin 2 receptor.","volume":"2","author":"Rubin","year":"1990","journal-title":"Cytokine"},{"key":"2019111806535764300_B20","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.2741\/1461","article-title":"Soluble interleukin-2 receptor in cancer.","volume":"9","author":"Murakami","year":"2004","journal-title":"Front Biosci"},{"issue":"3","key":"2019111806535764300_B21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1155\/MI.2005.121","article-title":"On the role of sIL-2R measurements in rheumatoid arthritis and cancers.","volume":"2005","author":"Witkowska","year":"2005","journal-title":"Mediators Inflamm"},{"issue":"11","key":"2019111806535764300_B22","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.4049\/jimmunol.136.11.4099","article-title":"A secreted form of the human interleukin 2 receptor encoded by an \u201canchor minus\u201d cDNA.","volume":"136","author":"Treiger","year":"1986","journal-title":"J Immunol"},{"issue":"8","key":"2019111806535764300_B23","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.4049\/jimmunol.141.8.2612","article-title":"Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition.","volume":"141","author":"Symons","year":"1988","journal-title":"J Immunol"},{"issue":"1","key":"2019111806535764300_B24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1096\/fj.99-1003rev","article-title":"The soluble interleukin 6 receptor: mechanisms of production and implications in disease.","volume":"15","author":"Jones","year":"2001","journal-title":"Faseb J"},{"issue":"24","key":"2019111806535764300_B25","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1073\/pnas.0600240103","article-title":"Converting IL-15 to a superagonist by binding to soluble IL-15Ralpha.","volume":"103","author":"Rubinstein","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2019111806535764300_B26","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.177.9.6072","article-title":"Combined IL-15\/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.","volume":"177","author":"Stoklasek","year":"2006","journal-title":"J Immunol"},{"issue":"3","key":"2019111806535764300_B27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/10408369991239196","article-title":"Soluble cytokine receptors: basic immunology and clinical applications.","volume":"36","author":"Fernandez-Botran","year":"1999","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"7","key":"2019111806535764300_B28","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1349-7006.2009.01167.x","article-title":"Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma.","volume":"100","author":"Morito","year":"2009","journal-title":"Cancer Sci"},{"issue":"4","key":"2019111806535764300_B29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/10428190500361029","article-title":"Aggressive non-Hodgkin\u2019s lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome.","volume":"47","author":"Fabre-Guillevin","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111806535764300_B30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1034\/j.1600-0609.2001.00334.x","article-title":"A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin\u2019s lymphoma.","volume":"66","author":"Niitsu","year":"2001","journal-title":"Eur J Haematol"},{"issue":"11","key":"2019111806535764300_B31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"issue":"3","key":"2019111806535764300_B32","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"2019111806535764300_B33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications.","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"2019111806535764300_B34","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood-2006-11-055756","article-title":"Nonredundant roles for Stat5a\/b in directly regulating Foxp3.","volume":"109","author":"Yao","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111806535764300_B35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/13543784.9.3.497","article-title":"Soluble cytokine receptors: novel immunotherapeutic agents.","volume":"9","author":"Fernandez-Botran","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"2019111806535764300_B36","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdn677","article-title":"Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.","volume":"20","author":"Ennishi","year":"2009","journal-title":"Ann Oncol"},{"issue":"7","key":"2019111806535764300_B37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/10428190802108888","article-title":"Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy.","volume":"49","author":"Oki","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111806535764300_B38","first-page":"1089","article-title":"Constitutive secretion of soluble interleukin-2 receptor by human T-cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.","volume":"144","author":"Wasik","year":"1994","journal-title":"Am J Pathol"},{"issue":"3","key":"2019111806535764300_B39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2567.2010.03308.x","article-title":"T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies.","volume":"131","author":"Lindqvist","year":"2010","journal-title":"Immunology"},{"issue":"3","key":"2019111806535764300_B40","first-page":"555","article-title":"Expression of IL-2 receptors in human melanoma cells.","volume":"13","author":"Rimoldi","year":"1993","journal-title":"Anticancer Res"},{"issue":"21","key":"2019111806535764300_B41","first-page":"5963","article-title":"Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ.","volume":"52","author":"Weidmann","year":"1992","journal-title":"Cancer Res"},{"issue":"1","key":"2019111806535764300_B42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0169-5002(96)00608-3","article-title":"Interleukin-2 receptors in pulmonary adenocarcinoma tissue.","volume":"16","author":"Yano","year":"1996","journal-title":"Lung Cancer"},{"issue":"5","key":"2019111806535764300_B43","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.4049\/jimmunol.130.5.2203","article-title":"The fate of interleukin-2 after in vivo administration.","volume":"130","author":"Donohue","year":"1983","journal-title":"J Immunol"},{"issue":"7","key":"2019111806535764300_B44","first-page":"2009","article-title":"Pharmacokinetics of recombinant interleukin 2 in humans.","volume":"50","author":"Konrad","year":"1990","journal-title":"Cancer Res"},{"issue":"3","key":"2019111806535764300_B45","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.4049\/jimmunol.182.3.1541","article-title":"Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses.","volume":"182","author":"Maier","year":"2009","journal-title":"J Immunol"},{"issue":"9","key":"2019111806535764300_B46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.it.2008.06.005","article-title":"Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other.","volume":"29","author":"Horwitz","year":"2008","journal-title":"Trends Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/10\/2809\/1317263\/zh803611002809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/10\/2809\/1317263\/zh803611002809.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T22:26:34Z","timestamp":1686176794000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/10\/2809\/28683\/Soluble-IL2R%CE%B1-facilitates-IL2mediated-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,8]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-03-340885","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,8]]}}}